Roivant Sciences (ROIV) was given a new $40.00 price target by Piper Sandler.
Roivant Sciences (ROIV): A Clinical Trial Win Meets a Phase 3 Failure [Yahoo! Finance]
Ohio governor: Vivek Ramaswamy faces little-known GOP challengers [USA TODAY]
Should Brepocitinib's New Trials and Batoclimab's Setback Require Action From Roivant Sciences (ROIV) Investors? [Yahoo! Finance]
Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript [Seeking Alpha]